Enorm volume al drie dagen.
Dit bedrijf heeft GEEN schuld.
TWST: What makes ADVENTRX a good investment?
Mr. Culley: As investors begin to return to the micro-cap markets, I think that ADVENTRX offers them a lower-risk regulatory path, shorter timelines to major value-creating events and hopefully a good return on their investment. Our shares are widely held with significant
trading volume, and we have an easy-to-understand story within a complex biotech space. I also think that much of our success next year will be driven by execution rather than by clinical risk. So as investors look at the health care sector, ADVENTRX is well poised to offer a comfortable place to make an investment in what is still a time of considerable
uncertainty.
TWST: Tell us about your background.
Mr. Culley: I’m fortunate to have spent many years on both the research and business side of this industry. The first half of my career was spent conducting academic research and working on drug development for a biotech company, and I have a master’s degree in biochemistry from UC, Santa Barbara. The second half of my career was spent as a Director and Vice President of business development, and I have an MBA from Cornell University. Being able to jump with facility between business and science has proven invaluable to me in my current role.
TWST: Is there anything that you’d like to add?
Mr. Culley: I think ADVENTRX is going to have a bright future. We’re delivering on our goals, we’re realistic about the challenges we face, and our recent financing success demonstrates our ability to adapt and thrive in difficult environments. We’ve moved away from high-risk, new chemical entities and costly in-house R&D activities and are focused on a business model that we believe will deliver high-value branded products with a limited investment and fairly short timelines.